{"product_id":"retatrutide-uae","title":"Retatrutide 60mg UAE – Research \u0026 Product Information","description":"\u003cp dir=\"ltr\"\u003e \u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cstrong\u003eDescription\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eRetatrutide 60mg UAE\u003c\/span\u003e\u003cspan\u003e is a product listing associated with retatrutide, an investigational compound being studied in clinical research. Retatrutide is also known by the development code LY3437943 and is being investigated as a triple receptor agonist involving the GIP, GLP-1 and glucagon pathways.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe compound has attracted substantial scientific interest because researchers are evaluating whether activity across these three receptor systems can influence body weight, metabolic health and other clinical outcomes.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eClinical research on retatrutide has progressed into Phase 3 and Phase 3b studies. Current ClinicalTrials.gov records include studies evaluating weight reduction, maintenance of weight reduction, safety and different dose-escalation approaches.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe Pureness X page currently lists a Retatrutide 60 mg product with a displayed price of AED 950. This is the price shown on the online product listing and should not be interpreted as an official UAE medicine price.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch1 dir=\"ltr\"\u003e\u003cspan\u003eWhat Is Retatrutide?\u003c\/span\u003e\u003c\/h1\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eRetatrutide, also known as LY3437943, is an investigational compound being developed for metabolic-health research.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eIts distinguishing scientific characteristic is activity across three receptor pathways:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli dir=\"ltr\"\u003e\n\u003cp dir=\"ltr\" role=\"presentation\"\u003e\u003cspan\u003eGLP-1 receptor\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli dir=\"ltr\"\u003e\n\u003cp dir=\"ltr\" role=\"presentation\"\u003e\u003cspan\u003eGIP receptor\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli dir=\"ltr\"\u003e\n\u003cp dir=\"ltr\" role=\"presentation\"\u003e\u003cspan\u003eGlucagon receptor\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eBecause of this combination, retatrutide is commonly described as a triple agonist.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe compound is being studied in clinical trials involving obesity and overweight populations, among other research areas. ClinicalTrials.gov currently lists Phase 3 and Phase 3b retatrutide studies.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch1 dir=\"ltr\"\u003e\u003cspan\u003eRetatrutide 60mg UAE Product Information\u003c\/span\u003e\u003c\/h1\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe Pureness X listing currently identifies this product as Retatrutide 60 mg and displays a price of AED 950.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eProduct Information\u003c\/span\u003e\u003c\/h3\u003e\n\u003cdiv dir=\"ltr\" align=\"left\"\u003e\n\u003ctable\u003e\n\u003ccolgroup\u003e\n\u003ccol width=\"162\"\u003e\n\u003ccol width=\"176\"\u003e\n\u003c\/colgroup\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eInformation\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eDetails\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eProduct name\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eRetatrutide 60 mg\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eResearch compound\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eRetatrutide\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eDevelopment code\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eLY3437943\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eListed strength\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003e60 mg\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eResearch mechanism\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eGLP-1 + GIP + glucagon\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eResearch classification\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eInvestigational\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eListed price\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eAED 950\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eGeographic topic\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eUAE\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe product-page information above reflects the current online listing and does not establish regulatory approval, clinical equivalence or product authenticity.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch1 dir=\"ltr\"\u003e\u003cspan\u003eHow Does the Retatrutide Triple-Agonist Approach Work?\u003c\/span\u003e\u003c\/h1\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eRetatrutide is being investigated because it interacts with three hormone-related receptor pathways.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eGLP-1 Pathway\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eGLP-1 signalling is associated with appetite regulation, satiety and glucose-related physiological processes.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eGIP Pathway\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eGIP is involved in glucose-dependent insulin signalling and metabolic processes.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eGlucagon Pathway\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eGlucagon is involved in energy metabolism and regulation of stored energy.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eResearchers are investigating whether combining these three pathways can produce meaningful changes in body weight and metabolic measures.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe triple-agonist mechanism is one of the major scientific features that distinguishes retatrutide from compounds acting primarily through a single receptor pathway.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch1 dir=\"ltr\"\u003e\u003cspan\u003eRetatrutide Clinical Research\u003c\/span\u003e\u003c\/h1\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eRetatrutide has progressed into later-stage clinical development.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eClinicalTrials.gov currently lists several Phase 3 and Phase 3b studies.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eFor example, TRIUMPH-6 is a Phase 3b study examining maintenance of weight reduction in people with obesity.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eTRIUMPH-8 is a Phase 3b study evaluating the efficacy and safety of retatrutide in people with obesity or overweight without type 2 diabetes.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eTRIUMPH-9 is another Phase 3 study examining different dose-escalation approaches in participants with obesity or overweight who do not have type 2 diabetes.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThere is also a Phase 3 study comparing retatrutide with tirzepatide in adults with obesity.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThese studies demonstrate ongoing clinical development. They do not mean that retatrutide has already become an approved medicine in every market.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch1 dir=\"ltr\"\u003e\u003cspan\u003eRetatrutide and Weight-Loss Research\u003c\/span\u003e\u003c\/h1\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eOne of the main areas of retatrutide research is body-weight reduction.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eResearchers are examining:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli dir=\"ltr\"\u003e\n\u003cp dir=\"ltr\" role=\"presentation\"\u003e\u003cspan\u003eChanges in body weight\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli dir=\"ltr\"\u003e\n\u003cp dir=\"ltr\" role=\"presentation\"\u003e\u003cspan\u003eWeight-maintenance outcomes\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli dir=\"ltr\"\u003e\n\u003cp dir=\"ltr\" role=\"presentation\"\u003e\u003cspan\u003eMetabolic measurements\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli dir=\"ltr\"\u003e\n\u003cp dir=\"ltr\" role=\"presentation\"\u003e\u003cspan\u003eSafety and tolerability\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli dir=\"ltr\"\u003e\n\u003cp dir=\"ltr\" role=\"presentation\"\u003e\u003cspan\u003eDifferences between research groups\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli dir=\"ltr\"\u003e\n\u003cp dir=\"ltr\" role=\"presentation\"\u003e\u003cspan\u003eLonger-term treatment outcomes\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe scientific purpose of clinical trials is to determine whether observed effects are meaningful, reproducible and sufficiently safe.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eIndividual results cannot be predicted from clinical-trial data alone.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch1 dir=\"ltr\"\u003e\u003cspan\u003eRetatrutide vs GLP-1 Research\u003c\/span\u003e\u003c\/h1\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eRetatrutide is sometimes discussed alongside GLP-1 medicines because one of its receptor targets is GLP-1.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eHowever, retatrutide is not simply a GLP-1-only compound.\u003c\/span\u003e\u003c\/p\u003e\n\u003cdiv dir=\"ltr\" align=\"left\"\u003e\n\u003ctable\u003e\n\u003ccolgroup\u003e\n\u003ccol width=\"188\"\u003e\n\u003ccol width=\"176\"\u003e\n\u003c\/colgroup\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eResearch compound\/type\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eReceptor pathways\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eGLP-1 agonist\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eGLP-1\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eGLP-1\/GIP dual agonist\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eGLP-1 + GIP\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eRetatrutide\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eGLP-1 + GIP + glucagon\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThis three-pathway activity is the central scientific feature behind the term triple agonist.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch1 dir=\"ltr\"\u003e\u003cspan\u003eWhat Is LY3437943?\u003c\/span\u003e\u003c\/h1\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eLY3437943 is the development code associated with retatrutide.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eResearchers and people following clinical development may encounter both terms:\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eRetatrutide\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eand\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eLY3437943\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003ein clinical-trial records and scientific literature.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eFor example, ClinicalTrials.gov uses “Retatrutide (LY3437943)” in multiple study records.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThis makes LY3437943 an important secondary research keyword for an informational page.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch1 dir=\"ltr\"\u003e\u003cspan\u003eRetatrutide Phase 3 Development\u003c\/span\u003e\u003c\/h1\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003ePhase 3 research represents a later stage of clinical development.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eCurrent ClinicalTrials.gov records show retatrutide being evaluated in multiple Phase 3 and Phase 3b studies. These studies are examining different populations and outcomes, including weight reduction, weight maintenance and safety.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe existence of Phase 3 trials should not be interpreted as proof of regulatory approval.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eClinical development and regulatory authorization are separate processes.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch1 dir=\"ltr\"\u003e\u003cspan\u003eRetatrutide UAE Regulatory Status\u003c\/span\u003e\u003c\/h1\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThis section is \u003c\/span\u003e\u003cspan\u003every important\u003c\/span\u003e\u003cspan\u003e for your UAE SEO page.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe Abu Dhabi Department of Health issued Circular No. 40\/2026 on 6 March 2026, warning healthcare facilities, healthcare professionals and the public against an unauthorized medical product identified as “Retatrutide.” The circular states that the product was being promoted online and that retatrutide remained under clinical development, with no authorized supply or legitimate distribution in global markets.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eTherefore, an online listing should not be presented as proof that retatrutide is an approved UAE medicine.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eImportant distinction\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eOnline product listing ≠ regulatory approval\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eClinical trial ≠ medicine authorization\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eListed price ≠ official UAE medicine price\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eProduct description ≠ proof of authenticity\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThis distinction is particularly important for anyone searching for Retatrutide 60mg UAE.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch1 dir=\"ltr\"\u003e\u003cspan\u003eIs Retatrutide Approved in the UAE?\u003c\/span\u003e\u003c\/h1\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eBased on the March 2026 Abu Dhabi Department of Health circular, retatrutide was identified as an unauthorized medical product and the authority warned against its use. The circular states that retatrutide remains under clinical development.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eFor this reason, this product page should \u003c\/span\u003e\u003cspan\u003enot\u003c\/span\u003e\u003cspan\u003e claim that retatrutide is an approved UAE weight-loss medicine or routinely available through UAE pharmacies.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch1 dir=\"ltr\"\u003e\u003cspan\u003eWhat Should Be Checked When Researching a Peptide Product?\u003c\/span\u003e\u003c\/h1\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003ePeople researching an online product listing should independently verify relevant information.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eImportant areas include:\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eProduct identity\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eConfirm the stated compound and strength.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eBatch information\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eCheck whether a specific batch or lot number is provided.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eLaboratory documentation\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eReview available laboratory documentation and determine exactly what was tested.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eCertificate of Analysis\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eWhere a COA is provided, check whether it relates to the actual batch.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eSupplier information\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eVerify the identity and provenance of the supplier.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eRegulatory status\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eCheck the latest requirements and warnings from the relevant UAE authority.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eIntended use\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eDo not automatically assume that an online research-product listing is equivalent to an approved pharmaceutical product.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch1 dir=\"ltr\"\u003e\u003cspan\u003eRetatrutide 60mg Price in UAE\u003c\/span\u003e\u003c\/h1\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe current Pureness X product page displays AED 950 for Retatrutide 60 mg.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eFor SEO purposes, it is reasonable to provide the current listed price, but it should be described as an online listing price rather than an official regulated medicine price.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eIf the Shopify price changes later, remember to update the text if you have manually mentioned AED 950 inside the description.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch1 dir=\"ltr\"\u003e\u003cspan\u003eRetatrutide Safety Research\u003c\/span\u003e\u003c\/h1\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eSafety evaluation remains an important component of retatrutide clinical development.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eClinical studies examine both potential effects and adverse events while monitoring participants under defined research protocols.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eResearch questions can include:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli dir=\"ltr\"\u003e\n\u003cp dir=\"ltr\" role=\"presentation\"\u003e\u003cspan\u003eOverall tolerability\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli dir=\"ltr\"\u003e\n\u003cp dir=\"ltr\" role=\"presentation\"\u003e\u003cspan\u003eGastrointestinal adverse events\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli dir=\"ltr\"\u003e\n\u003cp dir=\"ltr\" role=\"presentation\"\u003e\u003cspan\u003eMetabolic measurements\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli dir=\"ltr\"\u003e\n\u003cp dir=\"ltr\" role=\"presentation\"\u003e\u003cspan\u003eCardiovascular outcomes\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli dir=\"ltr\"\u003e\n\u003cp dir=\"ltr\" role=\"presentation\"\u003e\u003cspan\u003eTreatment discontinuation\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli dir=\"ltr\"\u003e\n\u003cp dir=\"ltr\" role=\"presentation\"\u003e\u003cspan\u003eLonger-term safety\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eBecause retatrutide remains investigational, research findings should not be converted into individual medical recommendations.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch1 dir=\"ltr\"\u003e\u003cspan\u003eFrequently Asked Questions\u003c\/span\u003e\u003c\/h1\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWhat is Retatrutide 60mg?\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eRetatrutide is an investigational compound also known as LY3437943. The Pureness X page currently lists a product identified as Retatrutide 60 mg.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWhat is LY3437943?\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eLY3437943 is the development code associated with retatrutide and is used in clinical research records.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWhat does triple agonist mean?\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eIt refers to retatrutide's investigation across three receptor pathways: GLP-1, GIP and glucagon.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eIs retatrutide approved in the UAE?\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe Abu Dhabi Department of Health issued a March 2026 warning identifying retatrutide as an unauthorized medical product and stating that it remains under clinical development.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eWhat is the listed price of Retatrutide 60mg UAE?\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThe Pureness X page currently displays AED 950. This is an online listing price, not an official regulated UAE medicine price.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eIs retatrutide a GLP-1-only compound?\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eNo. Retatrutide is being investigated as a triple agonist involving GLP-1, GIP and glucagon pathways.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2 dir=\"ltr\"\u003e\u003cspan\u003eIs Retatrutide in Phase 3?\u003c\/span\u003e\u003c\/h2\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eYes. Current ClinicalTrials.gov records show Phase 3 and Phase 3b retatrutide studies.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch1 dir=\"ltr\"\u003e\u003cspan\u003eResearch \u0026amp; Regulatory Disclaimer\u003c\/span\u003e\u003c\/h1\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThis content is provided for educational and research-information purposes only.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eRetatrutide remains an investigational compound and should not be represented as an approved UAE medicine.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eThis page does not provide individualized medical advice, dosing instructions, injection instructions or treatment recommendations.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eAn online product listing does not establish regulatory approval, authenticity, purity, safety or suitability for human use.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eAlways verify current UAE regulatory information and consult a qualified healthcare professional for medical questions.\u003c\/span\u003e\u003c\/p\u003e","brand":"Pharma Testostrone","offers":[{"title":"Default Title","offer_id":44629830205528,"sku":null,"price":950.0,"currency_code":"AED","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0745\/6315\/8104\/files\/Retatrutide_60mg_UAE_research_product.jpg?v=1787244920","url":"https:\/\/timewell.store\/products\/retatrutide-uae","provider":"Timewell","version":"1.0","type":"link"}